title: [Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].
abstract: Human recombinant erythropoietin constitutes a remarkable improvement in the treatment of uraemic anemia. Nevertheless, it causes haemorheological changes, which in turn may affect smaller blood vessel circulation. Our study was conducted on a pool of chronic uraemic patients under hemodialytic treatment who were given erythropoietin therapy. Substantial increases in overall blood viscosity and red cell aggregation were recorded, with no change in erythrocyte deformation. An increase in cardiovascular morbidity might occur in these patients who are already liable to this condition. Several years will have to elapse and thorough studies will have to be conducted on a large number of patients, to have conclusive evidence on this point.
authors.affiliation: Unità Operativa di Nefrologia e Dialisi, INRCA, Istituto Scientifico U. Sestilli, Ancona.
authors.forename: M
authors.initials: M
authors.lastname: Melappioni
authors.forename: R
authors.initials: R
authors.lastname: Giansanti
authors.forename: M
authors.initials: M
authors.lastname: Boemi
authors.forename: M
authors.initials: M
authors.lastname: Baldassari
authors.forename: S
authors.initials: S
authors.lastname: Baldini
authors.forename: T
authors.initials: T
authors.lastname: Pierangeli
authors.forename: R
authors.initials: R
authors.lastname: Radicioni
authors.forename: P
authors.initials: P
authors.lastname: Fumelli
authors.forename: N
authors.initials: N
authors.lastname: Panichi
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D001809:Blood Viscosity / Q000187:drug effects*; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004907:Erythrocyte Deformability / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood / Q000150:complications / Q000628:therapy
chemical_list: D006454:Hemoglobins; D007155:Immunologic Factors; D008055:Lipids; D011994:Recombinant Proteins; D004921:Erythropoietin; D005340:Fibrinogen
vernacular_title: Alterazioni emoreologiche in seguito a trattamento con eritropoietina umana ricombinante in pazienti emodializzati cronici.